The objective of this research is to make surgery for brain tumors and inflammatory lesions simpler and more precise by using fluorescent nanospheres to more easily visualize tumors
The oral solution formulation, which is a new dosage form of Aptivus, was also approved for treatment-experienced adults. The oral solution formulation will be available in the US
The study will include a maximum of 36 patients who are ineligible for platinum based chemotherapy. In the dose-escalation part of the study, six to 24 patients will
The initial results from this proof of concept study showed activity of lacosamide in fibromyalgia syndrome but require further analysis. A decision to start Phase IIb will be
In two Phase III trials evaluating Durezol in patients diagnosed with significant postoperative inflammation (more than 10 anterior chamber cells), Durezol was found to rapidly reduced inflammation and
Under a previously announced agreement, Sciele Pharma will exclusively market PrandiMet to physicians in the US. Sciele Pharma anticipates that PrandiMet will be available to physicians and patients
The collaboration provides Genzyme with exclusive worldwide rights to mipomersen, a novel lipid-lowering drug discovered and developed by Isis that is in Phase III clinical development. During the
Trinity Biotech’s HIV-1 Bed incidence assay is a second generation assay designed to detect recent HIV seroconversion by determination of the relative proportion of HIV specific IgG to
Frontage made an initial 20% equity investment in Advanced Biomedical Research (ABR) in 2007 and acquires the remaining 80% equity with the completion of this transaction. Frontage and
According to Laboratory Corporation of America (LabCorp), in a recent study of high risk and average risk subjects, this blood test, using six biomarkers and research conducted at
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.